Background: Extended-release levetiracetam (LEV-XR) has gained acceptance as an antiepileptic drug in dogs. No studies have evaluated its disposition in dogs with epilepsy.
| INTRODUCTION
Epilepsy is the most common chronic neurological disorder in dogs, 1 with an estimated prevalence of 0.6-0.75% in the general dog population. 2, 3 Approximately half of dogs with epilepsy are diagnosed with idiopathic epilepsy, a clinical syndrome characterized by ≥2
Abbreviations: AED, antiepileptic drug; AUC, area-under-the-curve for the plasma-concentration versus time profile; CL/F, clearance; C MAX , maximum plasma concentration; CV, coefficient of variation; HPLC, high-performance liquid chromatography; LEV, levetiracetam; LEV-XR, extended-release levetiracetam; NLME, nonlinear mixed effects; T MAX , time to maximum concentration; V/ F, volume of distribution unprovoked seizures at least 24 hours apart for which no underlying cause can be identified other than a confirmed or suspected genetic predisposition. 4 Antiepileptic drugs (AED) are the mainstay of treatment, and most dogs require lifelong treatment. Consequently, there is a continuous effort to introduce AED protocols into veterinary practice that will maximize seizure control while minimizing adverse medication-related effects.
Levetiracetam (LEV) is a second-generation AED that was approved for use in humans in 1999, and is being utilized with increasing frequency in veterinary medicine, both as a first line treatment and as add-on treatment. The drug possesses several favorable pharmacokinetic properties in dogs, including high PO bioavailability (100%), lack of hepatic metabolism and a wide therapeutic index. 
| MATERIALS AND METHODS

| Animals
Eighteen client-owned dogs with epilepsy were enrolled. All dogs had a presumptive diagnosis of idiopathic epilepsy based on at minimum a tier 1 level of confidence as outlined by the International Veterinary Epilepsy Task Force. 8 Six dogs were recruited into each of three groups based on their established maintenance AED treatment regimen: LEV-XR only (L group), LEV-XR in combination with phenobarbital (LP group), and LEV-XR in combination with zonisamide (LZ group). To be eligible for the study, all administered AEDs had to be at steady-state conditions, with repeated administration and no change in dose for a minimum amount of time equal to 5 half-lives for the drug. All dogs were being given generic formulations of the AEDs, representing various manufacturers. No other drugs were being administered aside from monthly parasitic preventatives.
Owners were required to provide informed consent before the dog's participation in the study. Nine dogs presented to NC State Veterinary Hospital for study participation, whereas the remaining 9 dogs presented to a regional veterinary hospital for sample collection according to a standardized study protocol. This study was approved by the Institutional Animal Care and Use Committee at NC State University.
| Sample collection
Owners were instructed to withhold food from their dogs overnight before participation in the study. Dogs presented to the hospital on the morning of the study and were admitted for the day. Blood samples were taken from each dog at five time points throughout the day:
immediately before administration of the morning dose of LEV-XR (0-hour sample), and at 2, 4, 8, and 12 hours after LEV-XR administration. At each sampling point,~6 mL of blood was collected from either the jugular, cephalic, or saphenous vein and placed in a sodium heparin tube (BD Vacutainer sodium heparin tubes; Becton, Dickinson and
Company, Franklin Lakes, NJ). Dogs were fed their regular diet at the time the morning dose of LEV-XR was administered, and were observed to consume their food. Other prescribed AEDs were administered in accordance with their established treatment schedule.
Water was available throughout the study. Blood samples were centrifuged after collection, and plasma harvested and frozen. Samples collected at outside sites were shipped to the investigators frozen and on ice by overnight delivery service. All samples were stored at −80 C until assayed.
| Drug analysis
Plasma LEV, phenobarbital, and zonisamide concentrations were measured using high-pressure liquid chromatography (HPLC) methods developed and validated in the author's (MGP) laboratory. The HPLC system components 9-11 and the method for analyzing LEV concentrations 9 have been described previously. Plasma phenobarbital and zonisamide concentrations were determined on 0-hour samples.
Phenobarbital concentrations were measured using an identical assay previously validated for cats. 12 A partial validation was used to adapt the assay for the study in dogs. Blank plasma from untreated dogs was fortified with phenobarbital to prepare quality control samples and a range of concentrations for a calibration curve. The calibration curve ranged from 1 to 60 μg/mL. with concentrations to make a calibration curve of five standards ranging from 0.5 to 100 μg/mL, as well as a zero sample to check for background noise and interfering peaks. After extraction with solidphase extraction cartridges, the eluent was dried, reconstituted with mobile phase, and 20 μL injected into the system. The mobile phase consisted of 30% acetonitrile and 70% buffer solution at a flow of 1 mL/min. Separation was achieved with a reverse-phase C-8 column and detection of peaks with ultraviolet (UV) absorbance at 215 nm.
The calibration curve was linear from the highest concentration down to the lower limit of quantification of 0.5 μg/mL (r 2 > 0.999). All samples incurred from the study were well above the lower limit of quantification for these assays. concentration. The primary parameters were calculated using the following formula:
| Description of pharmacokinetic model
Where C is the plasma LEV concentration, t is time after administration, k 01 is the non-IV absorption rate assuming first-order absorption, The model used steady-state conditions with the LEV dose in each group administered to steady state with an interval of every 12 hours.
| Population pharmacokinetics
Initial standard 2-stage analysis generated estimates for parameters in the model. These values were used as initial estimates for the population pharmacokinetic analysis. One dog in the LZ group was given a very high dose of LEV-XR (>200 mg/kg) and was excluded from the analysis. Because the study subjects were clinical patients, sampling times were at more sparse intervals than typically obtained from research animals. Therefore, to analyze these data with a sparse sampling design, a population pharmacokinetic analysis with nonlinear mixed effects (NLME) modeling 13, 14 was performed using commercial software (Phoenix NLME, Certara, St. Louis, MO).
Various models and different error structures were tested to determine the best fit base model. The model was parameterized according to Equation (1), and run with a quasi-random parametric expectation maximization (EM) algorithm using steady-state conditions with a dose administered every 12 hours. Final model selection was based on goodness-of-fit plots, statistical significance between models using −2LL (twice the negative log likelihood), Akaike information criterion (a goodness-of-fit measure based on the log likelihood adjusted for the number of parameters [degrees of freedom] in the fit), and coefficient of variation (CV%) of parameter estimates.
The model measured the fixed effects (typical values) for primary pharmacokinetic parameters and random effects attributed to interindividual (intersubject) variability. Secondary parameter estimates were obtained using standard compartmental equations.
After the final base model was obtained for the population, an examination of covariates was performed to determine if there were factors that could explain the variability in the primary parameters (k 01 , k 10 , and volume of distribution). The covariates examined were treatment group (L, LP, and LZ), LEV dose per dog (500, 750, 1000, and 1500 mg), body weight (kg), age (years), and sex (neutered male or spayed female). were used to explore their potential significance.
The covariates (treatment group, LEV dose per dog, body weight, age, and sex) were tested in a simple stepwise approach with forward inclusion and backward elimination. The effects of the covariate on a parameter were evaluated based on improvement in the −2LL. Results were considered statistically significant if the decrease was associated with a P value of <.01. If a significant covariate was identified, a backward elimination step was used to assess the significance of the covariate, and an increase in the −2LL with a P value of <.001. After 3 | RESULTS
| Dog demographics
Breeds represented in the study included mixed breed (n = 6),
Labrador retriever (n = 3), Australian shepherd (n = 2), and one each of Basset hound, Golden retriever, Pembroke Welsh corgi, Vizsla, Curly-coated retriever, and English springer spaniel. There were 11 spayed females and 6 neutered males, with a median body weight of 25.7 kg (range, 7.8-45.5 kg). Dogs were 3-12 years of age (median, 6 years) with a duration of epilepsy of 0.5-0.6 years (median, 1 year).
| AED administration
The mean PO dose of phenobarbital for dogs in the LP group was 23.52 mg/kg in the LZ group. To consider these differences, the LEV concentration was normalized to the mean study dose (29.4 mg/kg) for the pharmacokinetic analyses.
| Pharmacokinetic analysis using population model
The 
| DISCUSSION
We used a population pharmacokinetic approach and NLME modeling Abbreviations: LEV-XR, extended-release levetiracetam; CV, coefficient of variation; Ω 2 , variance of the random source error; AUC, area-under-the-curve for the plasma-concentration versus time profile; C MAX , peak concentration; θk 01 , theta (typical value) for absorption rate and associated half-life; θk 10 , theta for elimination rate and associated half-life; θV, theta for volume of distribution; T MAX , time to peak concentration. Clearance (CL) and V as shown in the table represent V/F and CL/F because they are calculated as per fraction absorbed for an oral dose. Values for Ω 2 and CV% are not available for secondary parameters (shown by "-") because random effects are only measured for primary parameters.
allow for an assessment of V and CL independent of fraction absorbed, it cannot be determined what factor is responsible for these differences. However, it seems most likely that the addition of phenobarbital affected the fraction of drug absorbed. Previous studies have identified a similar interaction between phenobarbital and the immediate release formulation of LEV in both healthy dogs 10 and dogs with epilepsy, 11 with significant differences reported for volume of distribution, clearance, AUC and C MAX . Phenobarbital administration may lead to induction of oxidative metabolism of LEV in dogs. 9 Although the location of the oxidative enzymes responsible for the increase in LEV metabolism is not known, it may be the liver or intestine, or both.
An increase in the presystemic metabolism of LEV at these sites would result in a smaller fraction of drug absorbed, which in turn would lead to an increase in PO drug clearance (CL/F) and V/F and a decrease in C MAX and AUC. 9 Because an accompanying IV dose was not administered to allow determination of the fraction absorbed (F), any change in F will result in an apparent change in CL/F and V/F, independent of any alteration in systemic CL or V.
Extended-release formulations are designed for drugs with short half-lives to prolong drug exposure by delaying the rate of release into the gastrointestinal tract, and thus allow for a longer dose interval.
Consequently, an extended-release drug formulation should have a longer T MAX with less fluctuation in maximum and minimum concentrations compared to the immediate release formulation. 15 The T MAX for LEV in our study population ranged from 3 to 4 hours, which is slightly longer than the reported T MAX of 1-3 hours for immediate release LEV in the dog. 5, 7, [9] [10] [11] Two previous studies evaluating the pharmacokinetics of LEV-XR in healthy dogs reported a T MAX range of 3-8 hours. 6, 7 One of these studies evaluated the effect of food on LEV-XR absorption, and determined that T MAX was prolonged in dogs given the PO dose of medication with food compared to dogs that were fasted, with mean values of 6.6 and 3.4 hours, respectively. 6 The authors concluded that administering the drug with food produced longer exposure to the extended-release formulation, because the presence of food has been shown to affect drug release from the stomach. 16 The dogs in our study were fed at the time of dosing, but had values for T MAX similar to those reported in the previous study for the fasted dogs. The second study reported a T MAX for LEV-XR of 5-8 hours after it was administered to healthy dogs in a fasting state. often is cited for use in veterinary medicine. However, data from our study indicate that some dogs will not maintain blood concentrations at a minimum concentration of 5 μg/mL with q12h dosing. Dogs concurrently receiving phenobarbital are at the greatest risk of concentrations <5 μg/mL using currently recommended dosages. Three of 6 dogs in the LP group had LEV concentrations <5 μg/mL at 2 of the sampling time points in the study, whereas 1 dog in the L group had an 0-hour sample of <5 μg/mL. Furthermore, if we aim for a higher minimum concentration of 10 μg/mL, then 59% of dogs (10 of 17) in our study would fall below this targeted concentration at ≥1 time points. This includes 100% of dogs (6 of 6) in the LP group, 50% of dogs (3 of 6) in the L group, and 20% of dogs (1 of 5) in the LZ group.
The majority of these low concentrations occurred at 0-or 12-hour sampling points, immediately before the next scheduled dosing of medication. This observation suggests that a higher dose of LEV-XR administered q12h may be needed in some dogs to maintain concentrations considered being therapeutic for human patients, and that monitoring should be utilized to optimize dosage.
In conclusion, we utilized a population pharmacokinetic model and identified considerable variation in pharmacokinetics and plasma drug concentrations in dogs with epilepsy treated with similar doses of LEV-XR, and determined that much of the variation could be attributed to concurrent administration of phenobarbital. In contrast, coadministration of zonisamide did not contribute to variability in LEV-XR pharmacokinetics in the population. These findings warrant consideration when utilizing LEV-XR as a treatment for epilepsy in dogs. Drug monitoring may be indicated to determine the most appropriate dose for an individual dog.
